Drug Trial Radar · NCT00917735
Green Tea and Reduction of Breast Cancer Risk
Last checked: Nov 19, 2026Latest source record: Feb 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,075
Actual
Start
Jul 2009
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 50 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
RATIONALE: Green tea extract contains ingredients (catechins) that may lower the risk of breast cancer. PURPOSE: This phase II trial is studying how well green tea extract works in preventing breast cancer compared to a placebo in postmenopausal women with high breast density. The investigators have hypothesized that green tea consumption reduces breast cancer risk, and this effect is seen primarily in women who have the low-activity COMT genotype. The investigators will test this by evaluating the effects of green tea extract on breast cancer biomarkers including mammographic density, plasma insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), estrone, estradiol, androstenedione, sex hormone binding globulin (SHBG), urinary estrogen metabolites and plasma F2-isoprostanes.
Conditions
- Breast Cancer
Interventions
Green tea extract supplementDrug
Two green tea extract capsules twice daily after breakfast and dinner for one year
PlaceboOther
Two placebo capsules twice daily after breakfast and dinner for one year
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mammographic DensityTime frame: Baseline and month 12
- Circulating Concentrations of Reproductive Hormones Including Estrone, Estradiol, Androstenedione, Testosterone, and Sex Hormone Binding Globulin (SHBG)Time frame: Baseline and month 12
- Circulating Concentrations of IGF Axis Proteins Including IGF-1 and IGFBP-3Time frame: Baseline and month 12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Fairview Southdale Breast Center
Edina, Minnesota
Fairview Maple Grove Breast Center
Maple Grove, Minnesota
University of Minnesota Medical Center (UMMC) Breast Clinic
Minneapolis, Minnesota
Park Nicollet Institute
Saint Louis Park, Minnesota
Food Science and Nutrition, University of Minnesota
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.